Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan

por OSAKO, TOMOFUMI, NISHIMURA, REIKI, NISHIYAMA, YASUYUKI, FUJISUE, MAMIKO
Publicado 2015

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis

por Nishimura, Reiki, Osako, Tomofumi, Okumura, Yasuhiro, Tashima, Rumiko, Toyozumi, Yasuo, Arima, Nobuyuki
Publicado 2011

Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer

por Nishimura, Reiki, Osako, Tomofumi, Okumura, Yasuhiro, Nakano, Masahiro, Otsuka, Hiroko, Fujisue, Mamiko, Arima, Nobuyuki
Publicado 2022

An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer

por Nishimura, Reiki, Osako, Tomofumi, Okumura, Yasuhiro, Nakano, Masahiro, Ohtsuka, Hiroko, Fujisue, Mamiko, Arima, Nobuyuki
Publicado 2022

Clinical Significance of CK19 Negative Breast Cancer

por Fujisue, Mamiko, Nishimura, Reiki, Okumura, Yasuhiro, Tashima, Rumiko, Nishiyama, Yasuyuki, Osako, Tomofumi, Toyozumi, Yasuo, Arima, Nobuyuki
Publicado 2012

Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study

por Tashima, Rumiko, Nishimura, Reiki, Osako, Tomofumi, Nishiyama, Yasuyuki, Okumura, Yasuhiro, Nakano, Masahiro, Fujisue, Mamiko, Toyozumi, Yasuo, Arima, Nobuyuki
Publicado 2015

The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index

por Arima, Nobuyuki, Nishimura, Reiki, Osako, Tomofumi, Nishiyama, Yasuyuki, Fujisue, Mamiko, Okumura, Yasuhiro, Nakano, Masahiro, Tashima, Rumiko, Toyozumi, Yasuo
Publicado 2016

Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III

por Takano, Toshimi, Ito, Mitsuya, Kadoya, Takayuki, Osako, Tomofumi, Aruga, Tomoyuki, Masuda, Norikazu, Miyaki, Toshiko, Niikura, Naoki, Shimizu, Daisuke, Yokoyama, Yuichi, Watanabe, Manabu, Tomomitsu, Masato, Aogi, Kenjiro
Publicado 2023

The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer

por Mori, Hitomi, Kubo, Makoto, Yamaguchi, Rin, Nishimura, Reiki, Osako, Tomofumi, Arima, Nobuyuki, Okumura, Yasuhiro, Okido, Masayuki, Yamada, Mai, Kai, Masaya, Kishimoto, Junji, Oda, Yoshinao, Nakamura, Masafumi
Publicado 2017

Microsatellite instability in Japanese female patients with triple-negative breast cancer

por Kurata, Kanako, Kubo, Makoto, Kai, Masaya, Mori, Hitomi, Kawaji, Hitomi, Kaneshiro, Kazuhisa, Yamada, Mai, Nishimura, Reiki, Osako, Tomofumi, Arima, Nobuyuki, Okido, Masayuki, Oda, Yoshinao, Nakamura, Masafumi
Publicado 2020

Granzyme B Expression in the Tumor Microenvironment as a Prognostic Biomarker for Patients with Triple-Negative Breast Cancer

por Mizoguchi, Kimihisa, Kawaji, Hitomi, Kai, Masaya, Morisaki, Takafumi, Hayashi, Saori, Takao, Yuka, Yamada, Mai, Shimazaki, Akiko, Osako, Tomofumi, Arima, Nobuyuki, Okido, Masayuki, Oda, Yoshinao, Nakamura, Masafumi, Kubo, Makoto
Publicado 2023

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer

por Mori, Hitomi, Kubo, Makoto, Nishimura, Reiki, Osako, Tomofumi, Arima, Nobuyuki, Okumura, Yasuhiro, Okido, Masayuki, Yamada, Mai, Kai, Masaya, Kishimoto, Junji, Miyazaki, Tetsuyuki, Oda, Yoshinao, Otsuka, Takao, Nakamura, Masafumi
Publicado 2016

T-bet(+) lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer

por Mori, Hitomi, Kubo, Makoto, Kai, Masaya, Yamada, Mai, Kurata, Kanako, Kawaji, Hitomi, Kaneshiro, Kazuhisa, Osako, Tomofumi, Nishimura, Reiki, Arima, Nobuyuki, Okido, Masayuki, Kishimoto, Junji, Oda, Yoshinao, Nakamura, Masafumi
Publicado 2019

Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2...

por Miyoshi, Yuichiro, Shien, Tadahiko, Ogiya, Akiko, Ishida, Naoko, Yamazaki, Kieko, Horii, Rie, Horimoto, Yoshiya, Masuda, Norikazu, Yasojima, Hiroyuki, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, Tomioka, Nobumoto, Wanifuchi-Endo, Yumi, Hosoda, Mitsuchika, Doihara, Hiroyoshi, Yamashita, Hiroko
Publicado 2019

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMA...

por Takahashi, Masato, Ohtani, Shoichiro, Nagai, Shigenori E., Takashima, Seiki, Yamaguchi, Miki, Tsuneizumi, Michiko, Komoike, Yoshifumi, Osako, Tomofumi, Ito, Yoshinori, Ikeda, Masahiko, Ishida, Kazushige, Nakayama, Takahiro, Takashima, Tsutomu, Asakawa, Takashi, Matsumoto, Sho, Shimizu, Daisuke, Masuda, Norikazu
Publicado 2020

Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast can...

por Miyoshi, Yuichiro, Shien, Tadahiko, Ogiya, Akiko, Ishida, Naoko, Yamazaki, Kieko, Horii, Rie, Horimoto, Yoshiya, Masuda, Norikazu, Yasojima, Hiroyuki, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, Tomioka, Nobumoto, Endo, Yumi, Hosoda, Mitsuchika, Doihara, Hiroyoshi, Miyoshi, Shinichiro, Yamashita, Hiroko
Publicado 2016